OCULAR THERAPEUTIX IN

Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ in Wet AMD

13 فبراير 2024 07:38:24 بحسب Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI™ in Wet AMD

25 يناير 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

18 ديسمبر 2023 16:01:00 بحسب Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces Pricing of Public Offering of Common Stock

13 ديسمبر 2023 22:09:58 بحسب Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock

13 ديسمبر 2023 16:01:11 بحسب Nasdaq GlobeNewswire

Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences

08 نوفمبر 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Ocular Therapeutix™ Provides Third Quarter 2023 Financial Results and Corporate Update

07 نوفمبر 2023 16:01:00 بحسب Nasdaq GlobeNewswire

Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for its First Pivotal Clinical Trial of OTX-TKI in Wet AMD

01 نوفمبر 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Ocular Therapeutix™ To Report Third Quarter 2023 Financial Results

24 أكتوبر 2023 08:00:01 بحسب Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces Initiation of its First Pivotal Clinical Trial of OTX-TKI in Wet AMD

03 أكتوبر 2023 16:01:00 بحسب Nasdaq GlobeNewswire

Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences

06 سبتمبر 2023 08:01:11 بحسب Nasdaq GlobeNewswire

Ocular Therapeutix™ to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference

09 أغسطس 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Ocular Therapeutix™ Provides Second Quarter 2023 Financial Results and Corporate Update

07 أغسطس 2023 16:01:00 بحسب Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces Appointment of New Board Member

12 يوليو 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Ocular Therapeutix™ Announces 12-Month Topline Data from Ongoing U.S.-Based Phase 1 Clinical Trial Evaluating OTX-TKI for Treatment of Wet AMD

10 يونيو 2023 18:30:00 بحسب Nasdaq GlobeNewswire

Ocular Therapeutix™ Completes Enrollment of the HELIOS Clinical Trial of OTX-TKI for the Treatment of Diabetic Retinopathy

07 يونيو 2023 08:00:01 بحسب Nasdaq GlobeNewswire

Ocular Therapeutix™ To Present 12-Month Top-Line Data from U.S.-Based Phase 1 Clinical Trial of OTX-TKI in Wet Age-Related Macular Degeneration at the 2023 Clinical Trials at the Summit Annual Meeting

05 يونيو 2023 16:01:00 بحسب Nasdaq GlobeNewswire

Ocular Therapeutix™ to Present at the Jefferies Global Healthcare Conference

01 يونيو 2023 08:00:01 بحسب Nasdaq GlobeNewswire

Ocular Therapeutix™ Provides First Quarter 2023 Financial Results and Corporate Update

08 مايو 2023 16:01:00 بحسب Nasdaq GlobeNewswire

Ocular Therapeutix™ to Present at the JMP Securities Life Sciences Conference

08 مايو 2023 08:00:00 بحسب Nasdaq GlobeNewswire